Obinutuzumab in Chinese Real-world Patients With iNHL
ConditionLymphomas Non-Hodgkin's B-Cell
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAffiliated Hospital of Nantong University
About this trial
This study aims to assess the clinical efficacy and safety of obinutuzumab in Chinese patients with indolent non-Hodgkin B-cell Lymphoma (predominantly Follicular lymphoma and Marginal zone lymphoma) in a real-world setting.
Eligibility criteria
Qualifiers
Age: Age ≥ 18 years at the start of treatment;
Be diagnosed with grade 1-3a follicular Lymphoma, Marginal zone lymphoma;
Previously untreated or relapsed or refractory patients;
Patients who started treatment with otuzumab between June 2021 and April 2023.
Disqualifiers
Patients currently participating or planning to participate in any interventional clinical trial;
Patients who, in the opinion of the investigator, are Discomfort for any other reason to participate in this study.
Trial design
Treatments tested in this trial
- Obinutuzumab
Treatment groups
400 Participants
are divided into 2 treatment groupsLocations
25Changzhou No.2 People's Hospital ChangzhouJiangsu, China
The First People's hospital of Changzhou ChangzhouJiangsu, China
Huai'an First People's hospital Huai'anJiangsu, China
Jiangyin People's Hospital JiangyinJiangsu, China
Sponsors and collaborators
Affiliated Hospital of Nantong University
Lead sponsor
Source ClinicalTrials.gov